PET/CT in the Staging of the Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

PET/CT in the Staging of the Non-Small-Cell Lung Cancer

Published:2012 Issue: Volume:2012 Page:1-8
ISSN:1110-7243
Container-title:Journal of Biomedicine and Biotechnology
language:en
Short-container-title:Journal of Biomedicine and Biotechnology

Author:

Chao Fangfang¹²³⁴,Zhang Hong¹²³⁴

Affiliation:

1. Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China

2. Zhejiang University Medical PET Center, Zhejiang University, Hangzhou 310009, China

3. Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou 310009, China

4. Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou 310009, China

Abstract

Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is emerging as a potential diagnosis and staging test in patients with non-small-cell lung cancer (NSCLC). The purpose of this paper is to discuss the value of integrated PET/CT in the staging of the non-small-cell lung cancer and its health economics.

Funder

National Natural Science Foundation of China

Publisher

Hindawi Limited

Subject

Health, Toxicology and Mutagenesis,Genetics,Molecular Biology,Molecular Medicine,General Medicine,Biotechnology

Link

http://downloads.hindawi.com/journals/bmri/2012/783739.pdf

Reference61 articles.

1. The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer

2. Cancer Statistics, 2008

3. PET and PET-CT of Lung Cancer